2010年自身免疫性肝病临床进展回顾

段维佳; 贾继东

2010年自身免疫性肝病临床进展回顾

首都医科大学附属北京友谊医院肝病中心

详细信息

中图分类号: R575
计量
- 文章访问数: 2725
- HTML全文浏览量: 8
- PDF下载量: 860
- 被引次数: 0
出版历程
- 收稿日期: 2011-02-16
- 出版日期: 2011-06-20

Clinical advances in autoimmune liver disease in 2010

摘要

摘要: 本文的目的在于回顾2010年原发性硬化性胆管炎、原发性胆汁性肝硬化、自身免疫性肝炎及重叠综合征在诊断、治疗及监测等方面的研究进展。
- 胆管炎,硬化性 /
- 肝硬化,胆汁性 /
- 肝炎,自身免疫性 /
- 重叠综合征
Abstract: The aim of this article is to review studies that improve the diagnosis, treatment and surveillance of primary sclerosing cholangitis, primary biliary cirrhosis, autoimmune hepatitis, and overlap syndromes in 2010.
- cholangitis /
- sclerosing /
- biliary cirrhosis primary /
- hepatitis autoimmune

HTML全文

参考文献(18)

[1]Chapman R, Fevery J, Kalloo A, et al.Diagnosis andmanagement of primary sclerosing cholangitis[J].Hepatology, 2010, 51 (2) :660-678.

[2]Dave M, Elmunzer BJ, Dwamena BA, et al.Primary sclerosingcholangitis:meta-analysis of diagnostic performance of MRcholangiopancreatography[J].Radiology, 2010, 256 (2) :387-396.

[3]European Association for the Study of the Liver.EASLclinical practice guidelines:management of cholestatic liverdiseases[J].J Hepatol, 2009, 51 (2) :237-267.

[4]Shi J, Li Z, Zeng X, et al.Ursodeoxycholic acid in primarysclerosing cholangitis:meta-analysis of randomized controlledtrials[J].Hepatol Res, 2009, 39 (9) :865-873.

[5]Sinakos E, Marschall HU, Lindor K, et al.Bile acid changes afterhigh-dose ursodeoxycholic acid treatment in primary sclerosingcholangitis:Relation to disease progression[J].Hepatology, 2010, 52 (1) :197-203.

[6]Barngarulingam SY, Bjornsson E, Enders F, et al.Long termoutcomes of positive fluorescence in situ hybridization (FISH) tests in primary sclerosing cholangitis[J].Hepatology, 2010, 51 (1) :174-180.

[7]Chapman WC.Fluorescent in situ hybridization testing in primarysclerosing cholangitis:useful testing or a random chanceresult[J].Hepatology, 2010, 51 (1) :16-19.

[8]Kaplan MM, Bonder A, Ruthazer R, et al.Methotrexate inpatients with primary biliary cirrhosis who respond incompletelyto treatment with ursodeoxycholic acid[J].Dig Dis Sci, 2010, 55 (11) :3207-3217.

[9]Rabahi N, Chrétien Y, Gaouar F, et al.Triple therapy withursodeoxycholic acid, budesonide and mycophenolate mofetilin patients with features of severe primary biliary cirrhosis notresponding to ursodeoxycholic acid alone[J].Gastroenterol ClinBiol, 2010, 34 (4-5) :283-287.

[10]Levy C, Peter JA, Nelson DR, et al.Pilot study:fenofibratefor patients with primary biliary cirrhosis and an incompleteresponse to ursodeoxycholic acid[J].Aliment Pharmacol Ther, 2011, 33 (2) :235-342.

[11]Hazzan R, Tur-Kaspa R.Bezafibrate treatment of primary biliarycirrhosis following incomplete response to ursodeoxycholicacid[J].J Clin Gastroenterol, 2010, 44 (5) :371-373.

[12]Silveira MG, Brunt EM, Heathcote J, et al.American Associationfor the Study of Liver Diseases endpoints conference:designand endpoints for clinical trials in primary biliary cirrhosis[J].Hepatology, 2010, 52 (1) :349-359.

[13]Manns MP, Czaja AJ, Gorham JD, et al.Diagnosis andmanagement of autoimmune hepatitis[J].Hepatology, 2010, 51 (6) :2193-2213.

[14]Bjrnsson E, Talwalkar J, Treeprasertsuk S, et al.Drug-inducedautoimmune hepatitis:clinical characteristics and prognosis[J].Hepatology, 2010, 51 (6) :2040-2048.

[15]Umemura T, Zen Y, Hamano H, et al.IgG4 associated autoimmunehepatitis:a differential diagnosis for classical autoimmunehepatitis[J].Gut, 2007, 56 (10) :1471-1472.

[16]Chung H, Watanabe T, Kudo M, et al.Identification andcharacterization of IgG4-associated autoimmune hepatitis[J].Liver Int, 2010, 30 (2) :222-231.

[17]Umemura T, Zen Y, Hamano H, et al.Clinical significance ofimmunoglobulin G4-associated autoimmune hepatitis[J].JGastroenterol, 2011, 46 (Suppl 1) :48-55.

[18]Boberg KM, Chapman RW, Hirschfield GM, et al.Overlapsyndromes:The International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue[J].JHepatol, 2011, 54 (2) :374-385.

施引文献

资源附件(0)

访问统计